Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ASP-9521 is an effective, specific and orally available AKR1C3 inhibitor (IC50: 11 nM, for human).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 39.00 | |
10 mg | In stock | $ 55.00 | |
25 mg | In stock | $ 117.00 | |
50 mg | In stock | $ 195.00 | |
100 mg | In stock | $ 355.00 | |
200 mg | In stock | $ 532.00 | |
500 mg | In stock | $ 815.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 43.00 |
Description | ASP-9521 is an effective, specific and orally available AKR1C3 inhibitor (IC50: 11 nM, for human). |
Targets&IC50 | AKR1C3:11 nM |
In vitro | ASP-9521 concentration-dependently inhibits conversion of androstenedione (AD) into androstenediol and testosterone (T) by recombinant human or cynomolgus monkey AKR1C3 (IC50: 11/49 nM, human/monkey). ASP-9521 has more than 100-fold selectivity for AKR1C3 over the isoform AKR1C2. In LNCaP-AKR1C3 cells, ASP-9521 suppresses AD-dependent PSA production and cell proliferation. |
In vivo | In CWR22R xenografts, ASP-9521 (3 mg/kg, p.o.) inhibits AD-induced intratumoural T production and this inhibitory effect is maintained for 24 h. ASP-9521 (p.o.) is rapidly eliminated from plasma, while its intratumoural concentration remained high. The bioavailability of ASP-9521 after oral administration (1 mg/kg) is 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively. |
Cell Research | LNCaP-AKR1C3 cells stably expressing human AKR1C3 are seeded in 96-well plates at 10000 cells/100 μL/well in RPMI-1640 medium supplemented with heat-inactivated charcoal-dextran-stripped FBS (1 % for the PSA expression assay and T measurement and 5 % for the cell proliferation assay). After 24 h incubation, AD is added to each well with or without ASP-9521 (0.3-100 nM). The cell culture media are collected 24 h after administration of AD to measure T concentration and 6 days after administration of AD to measure cell proliferation using Cell-Titer Glo assay. |
Animal Research | ASP-9521 is prepared in 0.5 % methyl cellulose.Mice carrying HEK293 or HEK293-AKR1C3 tumors with similar sizes are selected and randomly divided into 5 groups (N=3 for each group). All groups are treated with ASP-9521 (single oral administration; 3 mg/kg). Plasma (from the central vein) and tumor tissues are collected at 0.25, 0.5, 1, 2 and 4 h after administration of ASP-9521, and ASP-9521 concentrations are determined using the HPLCMS/MS method. |
Synonyms | ASP9521 |
Molecular Weight | 330.42 |
Formula | C19H26N2O3 |
CAS No. | 1126084-37-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 300 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ASP-9521 1126084-37-4 Metabolism NADPH Inhibitor inhibit ASP 9521 ASP9521 inhibitor